ClinicalTrials.gg
CompletedNCT02411591Updated Jul 9, 2020Results posted

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of Necitumumab and Abemaciclib in Carcinoma, Non-Small-Cell Lung and Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung — none open to participants now, 2 under way, none of them phase 3. necitumumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
7th of 13
66 · median 66
Started
2015
with 2 others
Phase 1
5 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
10 of 13
Eli Lilly and Company

Among the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 5 in phase 1, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About necitumumab

necitumumab: first FDA approval 2015 (PORTRAZZA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing necitumumab in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This is medical research evaluating the safety and efficacy of two new medicines (necitumumab and abemaciclib), administered in combination in participants affected by a defined type of advanced lung cancer (stage IV non-small-cell lung cancer).

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed NSCLC Stage IV:

    • Part A: NSCLC Stage IV (any type).
    • Part B: NSCLC Stage IV (squamous and nonsquamous).
  • at the time of study entry as defined by Version 1.1 (RECIST 1.1).
  • The participant must have progressed after platinum-based chemotherapy AND have received a maximum of 1 other prior chemotherapy for advanced and/or disease OR must be judged by the physician as ineligible for further standard chemotherapy. Prior treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and anaplastic lymphoma kinase (ALK) inhibitors is mandatory in participants whose tumor has EGFR-activating mutations or ALK translocations. Prior targeting agents and /adjuvant therapies are permitted with the exception of cyclin-dependent kinase (CDK)4/6-targeting agents or necitumumab.
  • The participant has tumor tissue available for biomarker analyses.
  • The participant has an performance status score of 0-1.
  • Have adequate organ functions.

Exclusion criteria

Exclusion Criteria:

  • The participant is currently enrolled in a clinical trial involving an product or non-approved use of a drug or device. Prior treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) - targeting agents or necitumumab is not permitted.
  • Have a serious concomitant systemic disorder or significant cardiac disease.
  • The participant has undergone major surgery or received any investigational therapy in the 30-days prior to study enrollment.
  • The participant has undergone chest irradiation within 4 weeks prior to receiving study treatment.
  • The participant has that are symptomatic.
  • History of arterial or venous thromboembolism within 3 months prior to study enrollment. Participants with a history of venous thromboembolism beyond 3 months prior to study enrollment can be enrolled if they are appropriately treated with low molecular weight heparin.
  • The participant has active infection requiring systemic therapy.
  • The participant has a known allergy / history of reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or abemaciclib, or any other to one of the administered treatments.
  • The participant is pregnant or breastfeeding.
  • The participant has a concurrent active . Previous history of malignancy is permitted, provided that the participant has been free of disease for ≥3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancers that in the judgment of the investigator and sponsor may not affect the interpretation of results (for example, prostate, bladder).
  • History of interstitial lung disease or an active non-infectious pneumonitis.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Necitumumab + Abemaciclib

    Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met. Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met. Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met. Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.

    Drug: Necitumumab · Drug: Abemaciclib

Interventions

  • Administered IV.

    Also known as: LY3012211

  • Administered orally.

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)

    A DLT was defined as one of the following adverse events (AEs), occurring in Cycle 1 if considered to be definitely, probably, or possibly related to necitumumab and abemaciclib: Grade 3 or 4 nonhematologic toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0), except for nausea, vomiting, diarrhea, or electrolyte disturbance. Grade 3 or 4 nausea, vomiting, or diarrhea that persists more than 2 days despite maximal supportive intervention. Grade 3 thrombocytopenia with bleeding requiring transfusion. Grade 4 thrombocytopenia with or without bleeding. Grade 4 neutropenia that persists more than 5 days.

    Time frame: Baseline through Cycle 1 (Up to 21 Days)

  2. Progression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months)

    PFS is defined as the time from baseline until first observation of progressive disease(PD) defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause.PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 millimeter (mm) or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization, regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis, the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.

    Time frame: Baseline to measured progressive disease or death due to any cause (3 Months)

Secondary outcomes

  1. Percentage of Participants Who Achieve Best Overall Tumor Response of Complete or Partial Response (Objective Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Confidence intervals are based on Clopper-Pearson method.

    Time frame: Baseline to measured progressive disease or start of new anti-cancer therapy (up to 21 months)

  2. Pharmacokinetics (PK): Predose Concentration (Cmin) of Necitumumab

    Predose necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.

    Time frame: Cycle 1, Day 8 (C1D8) and C2,3,5,7 D1: Predose

  3. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab

    Maximum necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.

    Time frame: Cycle 1, Day 1 (C1D1): 0.25, 2,4,10 hours(h) post dose, C1D8: 0.25h post dose, Cycle 2, Day 1 (C2D1): 0.25, 2,4,10h post dose; C3,5,7 D1: 0.25h post dose

  4. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib

    Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib.

    Time frame: Cycle 1, Day 1 (C1D1): 0.25, 2,4,6,8,10 hours(h) post dose, C1D8: 0.25h post dose, C2D1: 0.25, 2,4,6,8,10h post dose; C3,5,7 D1: 0.25h post dose

  5. Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC[0-tlast]) Abemaciclib

    Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC\[0-tlast\]) summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib. (tlast = 10 hours)

    Time frame: Cycle 1, Day 1 (C1D1): 0.25, 2,4,6,8,10 hours(h) post dose

  6. Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])

    Disease Control Rate (DCR) is defined as the percentage of participants achieving a best overall response of stable disease (SD), PR, or CR. DCR used the same denominator as defined in ORR. Among participants counted in the denominator, the numerator counted those with a confirmed best tumor response of SD, PR, or CR per RECIST v1.1. Confidence intervals are based on Clopper-Pearson method.

    Time frame: Baseline to measured progressive disease or start of new anti-cancer therapy (up to 21 months)

  7. Overall Survival

    Overall survival (OS) is defined as the time from the date of study enrollment to the date of death from any cause. For each participant who is not known to have died as of the data -inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date.

    Time frame: Baseline to date of death from any cause (24 Months)

07

Results

Posted Jul 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)
Started3576
Part a366
Expansion cohort part b0510
Progressive disease3423
Death020
Completed3473
Not completed0103
Withdrew: Adverse event042
Withdrew: Withdrawal by subject030
Withdrew: Physician decision031

Outcome measures

PrimaryPart A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)

A DLT was defined as one of the following adverse events (AEs), occurring in Cycle 1 if considered to be definitely, probably, or possibly related to necitumumab and abemaciclib: Grade 3 or 4 nonhematologic toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0), except for nausea, vomiting, diarrhea, or electrolyte disturbance. Grade 3 or 4 nausea, vomiting, or diarrhea that persists more than 2 days despite maximal supportive intervention. Grade 3 thrombocytopenia with bleeding requiring transfusion. Grade 4 thrombocytopenia with or without bleeding. Grade 4 neutropenia that persists more than 5 days.

Time frame:
Baseline through Cycle 1 (Up to 21 Days)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)
ParticipantsCohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumamab 800 mg + Abemaciclib 200 mg)
Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs)013
PrimaryProgression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months)

PFS is defined as the time from baseline until first observation of progressive disease(PD) defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause.PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 millimeter (mm) or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization, regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis, the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.

Time frame:
Baseline to measured progressive disease or death due to any cause (3 Months)
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months)
percentage of participantsCohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)
Progression Free Survival (PFS) Rate at 3 Months (Percentage of Participants With PFS at 3 Months)66.7 (5.4 to 94.5)32.3 (20.4 to 44.8)50.0 (11.1 to 80.4)
SecondaryPercentage of Participants Who Achieve Best Overall Tumor Response of Complete or Partial Response (Objective Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Confidence intervals are based on Clopper-Pearson method.

Time frame:
Baseline to measured progressive disease or start of new anti-cancer therapy (up to 21 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete or Partial Response (Objective Response Rate [ORR])
percentage of participantsCohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total Enrolled Participants (Necitumumab + Abemaciclib)
Overall Response Rate66.7 (9.4 to 99.2)5.3 (1.1 to 14.6)0.0 (0.0 to 45.9)7.6 (2.5 to 16.8)
PR66.7 (9.4 to 99.2)5.3 (1.1 to 14.6)0.0 (0.0 to 45.9)7.6 (2.5 to 16.8)
SD33.3 (0.8 to 90.6)42.1 (29.1 to 55.9)66.7 (22.3 to 95.7)43.9 (31.7 to 56.7)
PD0.0 (0.0 to 70.8)47.4 (34.0 to 61.0)16.7 (0.4 to 64.1)42.4 (30.3 to 55.2)
SecondaryPharmacokinetics (PK): Predose Concentration (Cmin) of Necitumumab

Predose necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.

Time frame:
Cycle 1, Day 8 (C1D8) and C2,3,5,7 D1: Predose
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
Pharmacokinetics (PK): Predose Concentration (Cmin) of Necitumumab
microgram/milliliter (μg/mL)Necitumumab
Cycle 1, Day 864.1 ± 43.1
Cycle 2, Day 149.6 ± 63.8
Cycle 3, Day 193.8 ± 44.1
Cycle 5, Day 1160 ± 50.3
Cycle 7, Day 1165 ± 42.1
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab

Maximum necitumumab concentration data following doses of 800 mg administered Day 1 and 8 of a 3-week cycle as an intravenous (IV) infusion over 60 minutes.

Time frame:
Cycle 1, Day 1 (C1D1): 0.25, 2,4,10 hours(h) post dose, C1D8: 0.25h post dose, Cycle 2, Day 1 (C2D1): 0.25, 2,4,10h post dose; C3,5,7 D1: 0.25h post dose
Reported as:
Geometric mean · μg/mL
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab
μg/mLNecitumumab
Cycle 1, Day 1228 ± 45.6
Cycle 1, Day 8 (D8)304 ± 21.9
Cycle 2, Day 1270 ± 25.6
Cycle 3, Day 1318 ± 43.7
Cycle 5, Day 1356 ± 42.7
Cycle 7, Day 1350 ± 24.7
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib.

Time frame:
Cycle 1, Day 1 (C1D1): 0.25, 2,4,6,8,10 hours(h) post dose, C1D8: 0.25h post dose, C2D1: 0.25, 2,4,6,8,10h post dose; C3,5,7 D1: 0.25h post dose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib
nanogram/milliliter (ng/mL)Abemaciclib 100 mgAbemaciclib 150 mgAbemaciclib 200 mg
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib15.6 ± 14626 ± 14838.2 ± 80
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC[0-tlast]) Abemaciclib

Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC\[0-tlast\]) summary of LSN3106729 noncompartmental PK parameters after twice daily oral dose of Abemaciclib. (tlast = 10 hours)

Time frame:
Cycle 1, Day 1 (C1D1): 0.25, 2,4,6,8,10 hours(h) post dose
Reported as:
Geometric mean · hour*nanogram/milliliter (hr*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC[0-tlast]) Abemaciclib
hour*nanogram/milliliter (hr*ng/mL)Abemaciclib 100 mgAbemaciclib 150 mgAbemaciclib 200 mg
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) From Zero to the Last Time Point (AUC[0-tlast]) Abemaciclib118 ± 200209 ± 136336 ± 83
SecondaryPercentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])

Disease Control Rate (DCR) is defined as the percentage of participants achieving a best overall response of stable disease (SD), PR, or CR. DCR used the same denominator as defined in ORR. Among participants counted in the denominator, the numerator counted those with a confirmed best tumor response of SD, PR, or CR per RECIST v1.1. Confidence intervals are based on Clopper-Pearson method.

Time frame:
Baseline to measured progressive disease or start of new anti-cancer therapy (up to 21 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])
percentage of participantsCohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total Enrolled Participants (Necitumumab + Abemaciclib)
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])100 (29.2 to 100.0)47.4 (34.0 to 61.0)66.7 (22.3 to 95.7)51.5 (38.9 to 64.0)
SecondaryOverall Survival

Overall survival (OS) is defined as the time from the date of study enrollment to the date of death from any cause. For each participant who is not known to have died as of the data -inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date.

Time frame:
Baseline to date of death from any cause (24 Months)
Reported as:
Median · Months
Overall Survival
MonthsCohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)
Overall SurvivalNA (18.20 to NA)6.93 (4.96 to 12.85)13.45 (1.31 to 18.53)

Adverse events

Collected over Up to 21 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Necitumumab 800 mg + Abemaciclib 100 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Necitumumab 800 mg + Abemaciclib 150 mg5/57 (8.8%)25/57 (43.9%)57/57 (100%)
Necitumumab 800 mg + Abemaciclib 200 mg2/6 (33.3%)4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventNecitumumab 800 mg + Abemaciclib 100 mgNecitumumab 800 mg + Abemaciclib 150 mgNecitumumab 800 mg + Abemaciclib 200 mg
CholecystitisHepatobiliary disorders1/30/570/6
Respiratory tract infectionInfections and infestations1/30/570/6
Infusion related reactionInjury, poisoning and procedural complications1/30/570/6
ThrombocytopeniaBlood and lymphatic system disorders0/30/571/6
PyrexiaGeneral disorders0/32/571/6
Anal abscessInfections and infestations0/30/571/6
HydronephrosisRenal and urinary disorders0/30/571/6
UreterolithiasisRenal and urinary disorders0/30/571/6
VomitingGastrointestinal disorders0/35/570/6
DiarrhoeaGastrointestinal disorders0/32/570/6
Most frequent other events
Showing 10 of 99
Most frequent other events
EventNecitumumab 800 mg + Abemaciclib 100 mgNecitumumab 800 mg + Abemaciclib 150 mgNecitumumab 800 mg + Abemaciclib 200 mg
FatigueGeneral disorders2/329/573/6
PyrexiaGeneral disorders2/310/572/6
ParonychiaInfections and infestations2/36/573/6
Decreased appetiteMetabolism and nutrition disorders2/321/574/6
HypokalaemiaMetabolism and nutrition disorders1/312/574/6
Dermatitis acneiformSkin and subcutaneous tissue disorders2/326/573/6
Dry skinSkin and subcutaneous tissue disorders2/315/574/6
DiarrhoeaGastrointestinal disorders1/329/573/6
AnaemiaBlood and lymphatic system disorders1/321/573/6
NauseaGastrointestinal disorders0/324/573/6

Baseline characteristics

All enrolled participants who received at least one dose of study drug. Cohort 2 includes total number of participants in Part A and evaluable participants of Part B.

Age, Continuous
Age, Continuous(years)Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total
Mean62.33 ± 2.3161.42 ± 10.5849.00 ± 7.5960.33 ± 10.68
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total
Female117119
Male240547
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total
Hispanic or Latino0202
Not Hispanic or Latino113115
Unknown or Not Reported242549
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White116118
More than one race0000
Unknown or Not Reported241548
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 (Necitumumab 800 mg + Abemaciclib 100 mg)Cohort 2 (Necitumumab 800 mg + Abemaciclib 150 mg)Cohort 3 (Necitumumab 800 mg + Abemaciclib 200 mg)Total
Belgium19111
France245552
Spain0303
08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Charleroi, 6000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Roeselare, 8800, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Brest, 29609, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Bron, 69677, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Marseille Cedex 05, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Montpellier, 34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Pau, 64046, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Strasbourg Cedex, 67091, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
    Villejuif, 94805, France
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 46014, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jun 2017, 24 months.

Results were first posted in Jul 2020, 3 years after primary completion.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 24 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2015
First posted
Apr 8, 2015
StartActual
Jun 4, 2015
Primary completionActual
Jun 23, 2017
CompletionActual
May 28, 2019
Results first posted
Jul 9, 2020
Last update
Jul 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02411591
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Jun 4, 2015
Primary completion
Jun 23, 2017
Completion
May 28, 2019
Results posted
Jul 9, 2020
Last update
Jul 9, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Necitumumab · Abemaciclib

Start the discussion